These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 22263625)

  • 21. [Recent prevention strategies and occupational risk analysis: Control Banding and Sobane].
    Ghittori S; Ferrari M; Negri S; Serranti P; Sacco P; Biffi R; Imbriani M
    G Ital Med Lav Ergon; 2006; 28(1):30-43. PubMed ID: 16705887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Occupational data cards as a source of information for health prevention purposes].
    Bugajska J
    Med Pr; 2000; 51(6):551-61. PubMed ID: 11288683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [International trend of guidance for nanomaterial risk assessment].
    Hirose A
    Yakugaku Zasshi; 2013; 133(2):175-80. PubMed ID: 23370509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanomaterial health effects part 3: conclusion--hazardous issues and the precautionary principle.
    Kanarek MS
    WMJ; 2007 Feb; 106(1):16-9. PubMed ID: 17393752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A method to assess the quality of studies that examine the toxicity of engineered nanomaterials.
    Card JW; Magnuson BA
    Int J Toxicol; 2010 Jul; 29(4):402-10. PubMed ID: 20634541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward.
    Lai DY
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(1):1-15. PubMed ID: 21965171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines.
    Warheit DB; Donner EM
    Nanotoxicology; 2010 Dec; 4():409-13. PubMed ID: 20925448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a globally harmonized system for hazard communication.
    Silk JC
    Int J Hyg Environ Health; 2003 Aug; 206(4-5):447-52. PubMed ID: 12971700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The applicability of chemical alternatives assessment for engineered nanomaterials.
    Hjorth R; Hansen SF; Jacobs M; Tickner J; Ellenbecker M; Baun A
    Integr Environ Assess Manag; 2017 Jan; 13(1):177-187. PubMed ID: 26887668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The OECD expert meeting on ecotoxicology and environmental fate--towards the development of improved OECD guidelines for the testing of nanomaterials.
    Kühnel D; Nickel C
    Sci Total Environ; 2014 Feb; 472():347-53. PubMed ID: 24461369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanomaterial health effects--part 1: background and current knowledge.
    Powell MC; Kanarek MS
    WMJ; 2006 Mar; 105(2):16-20. PubMed ID: 16628969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of reported flash point values on material safety data sheets and the impact on product classification.
    Radnoff D
    J Occup Environ Hyg; 2013; 10(10):540-6. PubMed ID: 24011179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk assessment and risk management of nanomaterials in the workplace: translating research to practice.
    Kuempel ED; Geraci CL; Schulte PA
    Ann Occup Hyg; 2012 Jul; 56(5):491-505. PubMed ID: 22752094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expert review for GHS classification of chemicals on health effects.
    Morita T; Morikawa K
    Ind Health; 2011; 49(5):559-65. PubMed ID: 21804272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a modified GreenScreen tool to conduct a screening-level comparative hazard assessment of conventional silver and two forms of nanosilver.
    Sass J; Heine L; Hwang N
    Environ Health; 2016 Nov; 15(1):105. PubMed ID: 27825359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hazard identification of inhaled nanomaterials: making use of short-term inhalation studies.
    Klein CL; Wiench K; Wiemann M; Ma-Hock L; van Ravenzwaay B; Landsiedel R
    Arch Toxicol; 2012 Jul; 86(7):1137-51. PubMed ID: 22532024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Hazards Not Communicated in Safety Data Sheets of Flavoring Formulations, Including Diacetyl and 2,3-Pentanedione.
    LeBouf RF; Hawley B; Cummings KJ
    Ann Work Expo Health; 2019 Jan; 63(1):124-130. PubMed ID: 30407491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Seveso II experience in the application of generic substance criteria to identify major hazard sites.
    Wood MH
    J Hazard Mater; 2009 Nov; 171(1-3):16-28. PubMed ID: 19632041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.